Previous close | 1.6400 |
Open | 1.6200 |
Bid | 1.5900 x 300 |
Ask | 1.6300 x 700 |
Day's range | 1.6000 - 1.6900 |
52-week range | 0.4100 - 1.7900 |
Volume | |
Avg. volume | 2,562,016 |
Market cap | 293.798M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024.
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.